74 related articles for article (PubMed ID: 20951313)
1. Somatic mutations of signaling genes in non-small-cell lung cancer.
Sanders HR; Albitar M
Cancer Genet Cytogenet; 2010 Nov; 203(1):7-15. PubMed ID: 20951313
[TBL] [Abstract][Full Text] [Related]
2. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
[TBL] [Abstract][Full Text] [Related]
3. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
[TBL] [Abstract][Full Text] [Related]
5. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.
Sonobe M; Nakagawa M; Takenaka K; Katakura H; Adachi M; Yanagihara K; Otake Y; Wada H; Tanaka F
J Surg Oncol; 2007 Jan; 95(1):63-9. PubMed ID: 17192868
[TBL] [Abstract][Full Text] [Related]
6. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
Riess JW; Wakelee HA
Clin Adv Hematol Oncol; 2012 Apr; 10(4):226-34. PubMed ID: 22706483
[TBL] [Abstract][Full Text] [Related]
7. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
[TBL] [Abstract][Full Text] [Related]
8. [Growth factor induced signal transduction in lung cancer].
Fujisaka Y; Saijo N
Nihon Rinsho; 2002 May; 60 Suppl 5():83-8. PubMed ID: 12101779
[No Abstract] [Full Text] [Related]
9. New driver mutations in non-small-cell lung cancer.
Pao W; Girard N
Lancet Oncol; 2011 Feb; 12(2):175-80. PubMed ID: 21277552
[TBL] [Abstract][Full Text] [Related]
10. [Targeting KRAS pathway in NSCLC therapy].
Le Moulec S; Loriot Y; Soria JC
Bull Cancer; 2009 Dec; 96 Suppl():S69-74. PubMed ID: 20034872
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapeutic targets in non-small cell lung cancer.
Dy GK; Adjei AA
Proc Am Thorac Soc; 2009 Apr; 6(2):218-23. PubMed ID: 19349491
[TBL] [Abstract][Full Text] [Related]
12. Multiplatform-based molecular subtypes of non-small-cell lung cancer.
Chen F; Zhang Y; Parra E; Rodriguez J; Behrens C; Akbani R; Lu Y; Kurie JM; Gibbons DL; Mills GB; Wistuba II; Creighton CJ
Oncogene; 2017 Mar; 36(10):1384-1393. PubMed ID: 27775076
[TBL] [Abstract][Full Text] [Related]
13. [Genetic analysis of brain tumors].
Tabuchi K; Shiraishi T
Nihon Rinsho; 2005 Sep; 63 Suppl 9():35-43. PubMed ID: 16201497
[No Abstract] [Full Text] [Related]
14. ROS1 gene rearrangement is identified in NSCLC.
Cancer Discov; 2012 Feb; 2(2):OF9. PubMed ID: 22585869
[TBL] [Abstract][Full Text] [Related]
15. Role of protein kinase B-dependent signaling in lung tumorigenesis.
Kurie JM
Chest; 2004 May; 125(5 Suppl):141S-4S. PubMed ID: 15136468
[TBL] [Abstract][Full Text] [Related]
16. Vistas in Non-Small Cell Lung Cancer (NSCLC) Treatment: of Kinome and Signaling Networks.
Stravopodis DJ; Papavassiliou KA; Papavassiliou AG
Int J Biol Sci; 2023; 19(7):2002-2005. PubMed ID: 37151885
[TBL] [Abstract][Full Text] [Related]
17. Novel therapies targeting signaling pathways in lung cancer.
Yagui-Beltrán A; He B; Raz D; Kim J; Jablons DM
Thorac Surg Clin; 2006 Nov; 16(4):379-96, vi. PubMed ID: 17240825
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of EGFR signaling: all mutations are not created equal.
Gazdar AF; Minna JD
PLoS Med; 2005 Nov; 2(11):e377. PubMed ID: 16288556
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of lung cancer signalling pathways: roadmap for therapies.
Brambilla E; Gazdar A
Eur Respir J; 2009 Jun; 33(6):1485-97. PubMed ID: 19483050
[TBL] [Abstract][Full Text] [Related]
20. Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond.
Amori G; Sugawara E; Inamura K
J Thorac Oncol; 2023 Nov; 18(11):e134-e135. PubMed ID: 37879772
[No Abstract] [Full Text] [Related]
[Next] [New Search]
